Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today the commercial launch of a small portable microplate reader for use with the company’s immunoassays and, ultimately, molecular diagnostics, providing new opportunities in point-of-care medicine. This affordable device enables Enzo to offer a complete solution to academic, CRO, and industrial customers.
Enzo is the provider of over 17,000 ELISA (enzyme-linked immunosorbent assay) and assay kits, including hundreds of highly sensitive ELISAs it manufactures. The advanced design and technology of Enzo’s compact microplate reader makes it possible to deliver precise and accurate results. Together with Enzo’s proprietary software, the device is an option for a wide variety of applications based on the miniaturization of Enzo’s assays. These tests include metabolites, hormones (e.g. pregnancy), proteins (e.g. inflammatory cytokines) and protein characterization.
With support from an instrument manufacturing company, the Enzo portable reader enables lab work to be executed outside of ...
